The Efficacy of Subconjunctival Bevacizumab in Diabetic Macular Edema
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 20
- 主要终点
- Central Macular Thickness
研究概览
简要总结
This study evaluates the effects of subconjunctivally injected bevacizumab in patients with diffuse diabetic macular edema.
详细描述
At baseline, the macular thicknesses of both eyes of the patients with persistant diabetic macular edema were measured by optical coherence tomography. After 3.75mg bevacizumab was injected into subconjunctival space of the eyes with diabetic macular edema. The measurements of the macular thicknesses were repeated by optical coherence tomography in 15th, 30th, 60th day after injections. The macular thickness measurements before and after injection were compared.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Having diffuse diabetic macular edema persisted at least 1 month
- •No intravitreal injection in last 3 months.
- •No retinal laser photocoagulation in last 6 months
- •Not have any other macular disease causing macular edema
排除标准
- •Having ischemic macula
- •Intravitreal injection in last 3 months.
- •Retinal laser photocoagulation in last 6 months
- •Have any other macular disease causing macular edema
研究组 & 干预措施
Diabetic macular edema
Bevacizumab (Altuzan) was injected subconjunctival space of the patients.
干预措施: Subconjunctival bevacizumab (Altuzan) (Drug)
结局指标
主要结局
Central Macular Thickness
时间窗: one year (between May 2015 and May 2016)
次要结局
未报告次要终点
研究者
Volkan YETER
MD
Neon Hospital